1. Home
  2. FIEE vs RNTX Comparison

FIEE vs RNTX Comparison

Compare FIEE & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiEE Inc

FIEE

FiEE Inc

N/A

Current Price

$6.90

Market Cap

45.6M

Sector

Utilities

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.16

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIEE
RNTX
Founded
1977
2001
Country
Hong Kong
United States
Employees
43
10
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.6M
47.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FIEE
RNTX
Price
$6.90
$1.16
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
9.2K
1.1M
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$1.00
52 Week High
$7.95
$2.22

Technical Indicators

Market Signals
Indicator
FIEE
RNTX
Relative Strength Index (RSI) 48.98 40.04
Support Level $6.60 $1.08
Resistance Level $7.66 $1.30
Average True Range (ATR) 0.55 0.15
MACD -0.05 -0.05
Stochastic Oscillator 62.81 13.64

Price Performance

Historical Comparison
FIEE
RNTX

About FIEE FiEE Inc

FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: